Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.

The acquisition of endocrine resistance is a common obstacle in endocrine therapy of patients with oestrogen receptor-α (ERα)-positive breast tumours. We previously demonstrated that the BIG3-PHB2 complex has a crucial role in the modulation of oestrogen/ERα signalling in breast cancer cells. Here we report a cell-permeable peptide inhibitor, called ERAP, ...
that regulates multiple ERα-signalling pathways associated with tamoxifen resistance in breast cancer cells by inhibiting the interaction between BIG3 and PHB2. Intrinsic PHB2 released from BIG3 by ERAP directly binds to both nuclear- and membrane-associated ERα, which leads to the inhibition of multiple ERα-signalling pathways, including genomic and non-genomic ERα activation and ERα phosphorylation, and the growth of ERα-positive breast cancer cells both in vitro and in vivo. More importantly, ERAP treatment suppresses tamoxifen resistance and enhances tamoxifen responsiveness in ERα-positive breast cancer cells. These findings suggest inhibiting the interaction between BIG3 and PHB2 may be a new therapeutic strategy for the treatment of luminal-type breast cancer.
Mesh Terms:
Amino Acid Sequence, Antineoplastic Agents, Binding Sites, Cell Line, Tumor, Cell Membrane, Cell Nucleus, Cell-Penetrating Peptides, Drug Resistance, Neoplasm, Estrogen Receptor alpha, Female, Gene Expression Regulation, Neoplastic, Histone-Lysine N-Methyltransferase, Humans, Molecular Sequence Data, Phosphorylation, Protein Binding, Repressor Proteins, Selective Estrogen Receptor Modulators, Signal Transduction, Tamoxifen
Nat Commun
Date: Sep. 21, 2013
Download Curated Data For This Publication
Switch View:
  • Interactions 14